Author of

• 31515

  +

  P2.14 - Targeted Therapy (ID 183)

  • Event: WCLC 2019
  • Type: Poster Viewing in the Exhibit Hall
  • Track: Targeted Therapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall

  • 31585

    +

    P2.14-65 - Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E–Mutant NSCLC in Real World Setting (ID 307)

    10:15 - 18:15  |  Author(s): Joelle Hobeika
    • Abstract
    • Slides

    Background
    

    Dabrafenib plus trametinib (D-T) combination is approved in Europe Union for BRAFV600E–mutant metastatic non-small cell lung cancer(NSCLC) but there is few published data’s on this efficacy and tolerance outside clinical trail results.

    Objective: to assess efficacy and tolerance of D-T in real world setting.

    Method
    

    Retrospective, multicentric study including BRAF V600E-positive advanced NSCLC receiving D-T outside a clinical trial. Overall survival (OS) and progression free survival (PFS) were analyzed in all population and according lines of D-T treatment (first line treatment or subsequent line treatments).

    Result
    

    the analysis included 40 BRAF V600E advanced NSCLC patients managed in 14 centers; at diagnosis: mean age 71 ±9.6 years , female 55 %, adenocarcinoma 95 %, currents/formers smokers 17.5%/50 %, At D-T initiation: PS 0-1/2 or+: 86.8%/13.2% , loss weight> 5%: 24%, symptomatic disease: 92%, stage IV: 95% , mean metastatic site: 2.3 (main metastatic sites: pleura: 46%, bone: 33%, respectively).Mean line of treatment before D-T: 1.5. D-T was a first line treatment in 22.5 %, second line or more 77.5% (25% received one BRAF TKI before). Median time between diagnosis and D-T treatment was 0.7 [95%CI: 0.2-1.3] months in first line setting and 17.3 [95%CI: 10.8-27.2] months.

    At the time of analysis 67.5% patients were in treatment with D-T and median follow up since beginning of D-T treatment was 8.7[95%CI: 5-12]months in whole population [7,5, 95%CI: 1-12.3]months for patients treated in first line). D-T dose was modified for 32.5.0% of the patients and definitively discontinued for 12,5 % because of severe adverse events.

    Median PFS and OS were not reach and follow up is continued.

    The mature results of PFS and OS (whole population and subgroups) will be showed to the WLCC meeting.

    Conclusion
    

    Section not applicable

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.